Arcuro Medical has raised a Series A round of funding led by Varana Capital. This funding round included participation from other notable investors, including Trendlines and Consensus Business Group.
The funding will support Arcuro’s next phase of growth and innovation. And the Series A remains open for additional investment, providing more opportunities for stakeholders to join in advancing Arcuro Medical’s impactful work in the medical device industry.
Arcuro Medical concluded a 2024 with several key achievements such as
— Establishing a new U.S. organization and hiring key sales leadership
— Adding new U.S. and international distribution partners
— Achieving a significant product development milestone with the 510(k) submission of a new product line
— Surpassing 5,000 global SuperBall cases
KEY QUOTES:
“Our investment in Arcuro Medical is a testament to the Varana Capital Chai Fund’s mission to support Israeli companies making a global impact. As the largest Israeli opportunity fund, the Chai Fund was created to invest in transformative innovations, and Arcuro’s revolutionary medical technology exemplifies this by providing better outcomes for orthopedic injuries. If you know any surgeons specializing in knees, please refer them to us: We are confident we can make a meaningful impact on their practice and, most importantly, their patients’ lives.”
– Varana Capital Co-Founder and CIO Ezra Gardner
“We are excited and grateful to welcome Varana Capital as the lead investor in our Series A, alongside our valued existing investors. Supported by this funding, our team is enthusiastic to kick off a strong 2025, delivering on our mission to assist surgeons in improving their patient’s quality of life.”
– Jamal Rushdy, Arcuro Medical’s CEO
